Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672253 | 1.00 | KMT2A (0.41) | KMT2ARECQLLMNAHTTALDH1A1 | |
| SCHEMBL5672285 | 0.90 | TDP1 (0.40) | KMT2ALMNAALDH1A1TDP1HSD11B1 | |
| SCHEMBL7495927 | 0.90 | TDP1 (0.40) | KMT2ALMNAALDH1A1TDP1HSD11B1 | |
| SCHEMBL7490542 | 0.89 | TDP1 (0.43) | KMT2ALMNAALDH1A1TDP1HSD11B1 | |
| SCHEMBL5671784 | 0.89 | TDP1 (0.43) | KMT2ALMNAALDH1A1TDP1HSD11B1 | |
| SCHEMBL28555501 | 0.87 | LMNA (0.42) | KMT2ALMNAHTTALDH1A1CASP1 | |
| SCHEMBL10452599 | 0.86 | LMNA (0.38) | KMT2ALMNAHTTALDH1A1VDR | |
| SCHEMBL5120356 | 0.83 | HSD11B1 (0.43) | KMT2ALMNAHTTALDH1A1VDR | |
| SCHEMBL31316 | 0.83 | HSD11B1 (0.43) | KMT2ALMNAHTTALDH1A1VDR | |
| SCHEMBL14141983 | 0.83 | HSD11B1 (0.43) | KMT2ALMNAHTTALDH1A1VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106928251-B | Preparation method of high-purity clopidogrel | 江苏天士力帝益药业有限公司 | 2021-05-04 | — | — | CN | disclosed |
| US-7153969-B2 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | SANOFI-AVENTIS (FR) | 2006-12-26 | — | — | US | disclosed |
| US-20040260110-A1 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | SANOFI (FR) | 2004-12-23 | — | — | US | disclosed |
| EP-1404681-A1 | PROCESS FOR THE PREPARATION OF TETRAHYDROTHIENO [3,2-C] PYRIDINE DERIVATIVES | Brantford Chemicals Inc. (CA) | 2004-04-07 | — | — | EP | disclosed |
| US-6573381-B1 | Useful as intermediates, notably for the synthesis of methyl (S)-2(2-chlorophenyl)-2(4,5,6,7-tetrahydrothieno(3,2-c)-5-pyridyl)acetate or clopidrogel | SANOFI-SYNTHELABO (FR) | 2003-06-03 | — | — | US | disclosed |
| WO-2003004502-A1 | PROCESS FOR THE PREPARATION OF TETRAHYDROTHIENO [3,2-C] PYRIDINE DERIVATIVES | BRANTFORD CHEMICALS INC. (CA) | 2003-01-16 | — | — | WO | disclosed |
| US-6495691-B1 | THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, WHEREIN THE MEANING OF X IS HYDROGEN, CARBOXYL, ALKOXYCARBONYL, ARYLOXYCARBONYL, NITRILE, OR CARBAMOYL OF THE FORMULA TICLOPIDINE, IS AN ANTITHROMBOTIC DRUG WITH PLATELET AGGREGATION INHIBITING | BRANTFORD CHEMICALS INC. (CA) | 2002-12-17 | — | — | US | disclosed |
| EP-1021449-B1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI SYNTHELABO (FR) | 2002-01-02 | — | — | EP | disclosed |
| EP-1021449-A1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999018110-A1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260110-A1 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | HAAO, HTR3C, HTR3A | KMT2A 417/4885RECQL 3591/4885LMNA 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.